Anorexia News and Research

RSS

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015.

8 May 2015

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Amgen today announced that the European Commission approved a new use of Vectibix (panitumumab) as first-line treatment in combination with FOLFIRI for the treatment of adult patients with wild-type (WT) RAS metastatic colorectal cancer (mCRC).

6 Apr 2015

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Helsinn, a Swiss Group focused on building quality cancer care, and Mundipharma, today announce that they have entered into a distribution and license agreement for the exclusive rights to anamorelin in China, Hong Kong and Macao.

26 Mar 2015

Anorexics’ brains are wired differently, shows study

Researchers at the University of California, San Diego School of Medicine have pinpointed differences in brain function that may help to explain how people with anorexia nervosa can continue to starve themselves, even when already emaciated.

24 Mar 2015

Appetite-controlling neurons initiate repetitive behaviors seen in OCD, anorexia nervosa

In the absence of food, neurons that normally control appetite initiate complex, repetitive behaviors seen in obsessive-compulsive disorder (OCD), and anorexia nervosa, according to a new study by Yale School of Medicine researchers.

9 Mar 2015

Study finds similar brain anomalies in people with anorexia and body dysmorphic disorder

People with anorexia nervosa and with body dysmorphic disorder have similar abnormalities in their brains that affect their ability to process visual information, a new UCLA study reveals.

9 Mar 2015

Rogers Behavioral Health announces addition of eating disorder program to Tampa location

Rogers Behavioral Health-Tampa Bay announced today that it is adding a partial hospitalization eating disorder program to its Tampa location beginning March 30. This news is particularly timely as the nation recognizes National Eating Disorder Awareness Week February 22-28.

23 Feb 2015

Philadelphia College of Osteopathic Medicine professor explores causes, treatments of anorexia

Eating disorders are serious, debilitating conditions associated with significant morbidity and mortality, and distress. Anorexia nervosa, in particular, is associated with the highest mortality and suicide rates; compared to healthy peers, women with anorexia are up to 12 times more likely to die of any cause, and approximately 57 times more likely to die from suicide, over the same period of time.

20 Feb 2015

New study sheds light on anorexia nervosa

A study led by Howard Steiger, PhD, head of the Douglas Mental Health University Institute Eating Disorders Program, in Montreal, in collaboration with Linda Booij, a researcher with Sainte-Justine Hospital and an assistant professor at Queen's University, is the first to observe effects suggesting that the longer one suffers from active anorexia nervosa (AN), the more likely they are to show disorder-relevant alterations in DNA methylation.

9 Feb 2015

Study: Teens who perceive themselves as overweight are at greater risk of obesity as adults

Teens who mistakenly perceive themselves as overweight are actually at greater risk of obesity as adults, according to research findings forthcoming in Psychological Science, a journal of the Association for Psychological Science.

2 Feb 2015

Shire announces FDA approval of Vyvanse Capsules for binge eating disorder

Shire plc announced today that the U.S. Food and Drug Administration approved Vyvanse (lisdexamfetamine dimesylate) Capsules (CII), the first and only medication for the treatment of moderate to severe binge eating disorder (B.E.D.) in adults, shown to significantly reduce the mean number of binge days per week.

30 Jan 2015

LCS Therapeutics collaborates to commercialize patent on method to treat binge eating disorder

LCS Therapeutics announced today that it has entered into a strategic collaboration with Lucerne Biosciences, LLC to commercialize U.S. Patent No. 8,318,813 entitled "Method of Treating Binge Eating Disorder."

26 Dec 2014

Researchers use MRI techniques to study consequences of anorexia nervosa on brain structure

Researchers from the Translational Developmental Neuroscience Lab led by Professor Stefan Ehrlich at the Department of Child and Adolescent Psychiatry and Psychotherapy of the University Hospital Carl Gustav Carus at the TU Dresden (Faculty of Medicine) used state-of-the-art magnetic resonance imaging (MRI) techniques to investigate the consequences of anorexia nervosa on brain structure.

3 Dec 2014

The Female Athlete Triad: A medical condition in active girls and women

Sophie is a 15 year old cross country runner who has a history of a foot stress fracture and shin splints. Often she does not eat prior to her workouts.

17 Oct 2014

Researchers demonstrate involvement of ClpB protein in eating disorders

Eating disorders (ED) such as anorexia nervosa, bulimia, and binge eating disorder affect approximately 5-10% of the general population, but the biological mechanisms involved are unknown. Researchers at Inserm Unit 1073, "Nutrition, inflammation and dysfunction of the gut-brain axis" (Inserm/University of Rouen) have demonstrated the involvement of a protein produced by some intestinal bacteria that may be the source of these disorders.

7 Oct 2014

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

A new drug, anamorelin, improves appetite and body mass in patients with advanced lung cancer who are suffering cancer anorexia and cachexia, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Helsinn to present Phase III trial data of anamorelin at ESMO Congress

Helsinn Group, a company focused on building quality cancer care, today announces that Phase III data from the largest trial program of its kind to date in anamorelin, a novel, once-daily ghrelin receptor agonist in development for cancer-anorexia-cachexia (CACS) in non-small cell lung cancer will be presented at the 38th European Society for Medical Oncology Congress in Madrid, Spain, in 2014.

25 Sep 2014

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.

11 Sep 2014

Simple question about appetite may help reduce risk of dying

A simple question about appetite can provide insights into old people's general health that may help reduce their risk of dying.